-transparent.png){kind=logo}
Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors. 2019
Zhe Nie, and
Lihong Shi, and
Chon Lai, and
Christophe Severin, and
Jiangchun Xu, and
Joselyn R Del Rosario, and
Ryan K Stansfield, and
Robert W Cho, and
Toufike Kanouni, and
James M Veal, and
Jeffrey A Stafford, and
Young K Chen
Celgene Corporation, 10300 Campus Point Drive, Suite 100, San Diego, CA 92121, USA.
The histone demethylase LSD1 is a key enzyme in the epigenetic regulation of gene transcription. Here we present our efforts to discover small molecule reversible inhibitors of LSD1 as an attractive approach to treat hematologic malignancies and certain solid tumors. Using structure-based drug design, we designed and synthesized a novel series of heteroaromatic imidazole inhibitors that demonstrate potent inhibition of the demethylase activity and low nanomolar cell-based activity. This novel LSD1 inhibitor series was further optimized by attenuating the hERG inhibition and improving oral bioavailability.
Related Publications
Zhe Nie, and
Lihong Shi, and
Chon Lai, and
Christophe Severin, and
Jiangchun Xu, and
Joselyn R Del Rosario, and
Ryan K Stansfield, and
Robert W Cho, and
Toufike Kanouni, and
James M Veal, and
Jeffrey A Stafford, and
Young K Chen
December 2017,
European journal of medicinal chemistry,
Zhe Nie, and
Lihong Shi, and
Chon Lai, and
Christophe Severin, and
Jiangchun Xu, and
Joselyn R Del Rosario, and
Ryan K Stansfield, and
Robert W Cho, and
Toufike Kanouni, and
James M Veal, and
Jeffrey A Stafford, and
Young K Chen
September 2006,
Proceedings of the National Academy of Sciences of the United States of America,
Zhe Nie, and
Lihong Shi, and
Chon Lai, and
Christophe Severin, and
Jiangchun Xu, and
Joselyn R Del Rosario, and
Ryan K Stansfield, and
Robert W Cho, and
Toufike Kanouni, and
James M Veal, and
Jeffrey A Stafford, and
Young K Chen
October 2019,
Journal of biomolecular structure & dynamics,
Zhe Nie, and
Lihong Shi, and
Chon Lai, and
Christophe Severin, and
Jiangchun Xu, and
Joselyn R Del Rosario, and
Ryan K Stansfield, and
Robert W Cho, and
Toufike Kanouni, and
James M Veal, and
Jeffrey A Stafford, and
Young K Chen
March 2021,
Journal of medicinal chemistry,
Zhe Nie, and
Lihong Shi, and
Chon Lai, and
Christophe Severin, and
Jiangchun Xu, and
Joselyn R Del Rosario, and
Ryan K Stansfield, and
Robert W Cho, and
Toufike Kanouni, and
James M Veal, and
Jeffrey A Stafford, and
Young K Chen
January 2017,
European journal of medicinal chemistry,
Zhe Nie, and
Lihong Shi, and
Chon Lai, and
Christophe Severin, and
Jiangchun Xu, and
Joselyn R Del Rosario, and
Ryan K Stansfield, and
Robert W Cho, and
Toufike Kanouni, and
James M Veal, and
Jeffrey A Stafford, and
Young K Chen
March 2022,
Journal of medicinal chemistry,
Zhe Nie, and
Lihong Shi, and
Chon Lai, and
Christophe Severin, and
Jiangchun Xu, and
Joselyn R Del Rosario, and
Ryan K Stansfield, and
Robert W Cho, and
Toufike Kanouni, and
James M Veal, and
Jeffrey A Stafford, and
Young K Chen
January 2018,
RSC advances,
Zhe Nie, and
Lihong Shi, and
Chon Lai, and
Christophe Severin, and
Jiangchun Xu, and
Joselyn R Del Rosario, and
Ryan K Stansfield, and
Robert W Cho, and
Toufike Kanouni, and
James M Veal, and
Jeffrey A Stafford, and
Young K Chen
January 2018,
European journal of medicinal chemistry,
Zhe Nie, and
Lihong Shi, and
Chon Lai, and
Christophe Severin, and
Jiangchun Xu, and
Joselyn R Del Rosario, and
Ryan K Stansfield, and
Robert W Cho, and
Toufike Kanouni, and
James M Veal, and
Jeffrey A Stafford, and
Young K Chen
January 2022,
European journal of medicinal chemistry,
Zhe Nie, and
Lihong Shi, and
Chon Lai, and
Christophe Severin, and
Jiangchun Xu, and
Joselyn R Del Rosario, and
Ryan K Stansfield, and
Robert W Cho, and
Toufike Kanouni, and
James M Veal, and
Jeffrey A Stafford, and
Young K Chen
May 2017,
Bioorganic & medicinal chemistry letters,
